KRAL activation promotes chemo-sensitization to HCC cells by targeting the miR-141/KEAP1 axis as a competing endogenous RNA (ceRNA), with a consequent upregulation of KEAP1 and a silencing of NFE2L2, respectively [71]. This evidence concerns the gene NFE2L2 and hepatocellular carcinoma.